Loffroy Romaric, Favelier Sylvain, Chevallier Olivier, Estivalet Louis, Genson Pierre-Yves, Pottecher Pierre, Gehin Sophie, Krausé Denis, Cercueil Jean-Pierre
Department of Vascular, Oncologic and Interventional Radiology, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, François-Mitterrand Teaching Hospital, Dijon Cedex, France.
Quant Imaging Med Surg. 2015 Oct;5(5):730-9. doi: 10.3978/j.issn.2223-4292.2015.10.04.
Postoperative liver failure is a severe complication of major hepatectomies, in particular in patients with a chronic underlying liver disease. Portal vein embolization (PVE) is an approach that is gaining increasing acceptance in the preoperative treatment of selected patients prior to major hepatic resection. Induction of selective hypertrophy of the non-diseased portion of the liver with PVE in patients with either primary or secondary hepatobiliary, malignancy with small estimated future liver remnants (FLR) may result in fewer complications and shorter hospital stays following resection. Additionally, PVE performed in patients initially considered unsuitable for resection due to lack of sufficient remaining normal parenchyma may add to the pool of candidates for surgical treatment. A thorough knowledge of hepatic segmentation and portal venous anatomy is essential before performing PVE. In addition, the indications and contraindications for PVE, the methods for assessing hepatic lobar hypertrophy, the means of determining optimal timing of resection, and the possible complications of PVE need to be fully understood before undertaking the procedure. Technique may vary among operators, but cyanoacrylate glue seems to be the best embolic agent with the highest expected rate of liver regeneration for PVE. The procedure is usually indicated when the remnant liver accounts for less than 25-40% of the total liver volume. Compensatory hypertrophy of the non-embolized segments is maximal during the first 2 weeks and persists, although to a lesser extent during approximately 6 weeks. Liver resection is performed 2 to 6 weeks after embolization. The goal of this article is to discuss the rationale, indications, techniques and outcomes of PVE before major hepatectomy.
术后肝衰竭是大肝切除术后的一种严重并发症,尤其是在患有慢性基础肝病的患者中。门静脉栓塞术(PVE)是一种在大型肝切除术前对选定患者进行术前治疗时越来越被接受的方法。对于原发性或继发性肝胆恶性肿瘤且预计未来肝残余量(FLR)较小的患者,通过PVE诱导肝脏非病变部分的选择性肥大,可能会减少切除术后的并发症并缩短住院时间。此外,对于最初因剩余正常实质不足而被认为不适合切除的患者进行PVE,可能会增加手术治疗的候选人群。在进行PVE之前,全面了解肝脏分段和门静脉解剖结构至关重要。此外,在进行该手术之前,需要充分了解PVE的适应证和禁忌证、评估肝叶肥大的方法、确定最佳切除时机的手段以及PVE可能的并发症。不同操作者的技术可能有所不同,但氰基丙烯酸酯胶似乎是PVE中预期肝再生率最高的最佳栓塞剂。当残余肝占全肝体积的比例小于25% - 40%时,通常会进行该手术。未栓塞节段的代偿性肥大在最初2周内最大,并会持续,尽管在大约6周内程度会减轻。栓塞术后2至6周进行肝切除。本文的目的是讨论大肝切除术前PVE的基本原理、适应证、技术和结果。